Share on StockTwits

Investment analysts at Brean Capital began coverage on shares of Mirati Therapeutics (NASDAQ:MRTX) in a note issued to investors on Tuesday. The firm set a “buy” rating and a $27.00 price target on the stock. Brean Capital’s price objective suggests a potential upside of 52.46% from the stock’s previous close.

In other Mirati Therapeutics news, major shareholder Orbimed Advisors Llc sold 107,332 shares of Mirati Therapeutics stock on the open market in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $21.66, for a total value of $2,324,811.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Mirati Therapeutics (NASDAQ:MRTX) traded down 3.78% on Tuesday, hitting $17.04. 18,762 shares of the company’s stock traded hands. Mirati Therapeutics has a one year low of $7.00 and a one year high of $25.97. The stock’s 50-day moving average is $20.27 and its 200-day moving average is $19.83. The company’s market cap is $229.6 million.

MRTX has been the subject of a number of other recent research reports. Analysts at JMP Securities reiterated a “market outperform” rating on shares of Mirati Therapeutics in a research note on Monday, June 16th. They now have a $28.00 price target on the stock, up previously from $25.00. Analysts at Zacks upgraded shares of Mirati Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Thursday, April 10th. They now have a $19.40 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Mirati Therapeutics has an average rating of “Buy” and a consensus target price of $27.10.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.